Skip to main content

CCTG trials in development update Q3 2025

CCTG trials in development update 2025 Q3

2025 Q3 Planned trials

  • ALC9 (HEMATOLOGIC) Q4 2025 
    myeloMATCH  - (ERASE) Eradicating MRD in Patients with AML prior to Stem Cell Transplant 
     
  • ALC10 (HEMATOLOGIC) Q4 2025 
    myeloMATCH - Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML 
     
  • MD1 (HEMATOLOGIC) Q2 2026 
    myeloMATCH - (CALMS) Combination Therapy with Luspatercept in Lower Risk MDS 
     
  • CE10 (BRAIN) Q4 2025
    (VIGOR) Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma 
     
  • HN14  (HEAD & NECK) Q2 2026 
    (REVERT) Delayed Reduced Volume and Dose Elective Ratiotherapy in Patients with HNSCC 
     
  • ME18 (MELANOMA) Q3 2026 
    (MSLT-3) The Multicentre Selective Lymphadenectomy Trial-3 - Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma
     
  • PAC5 (GASTRO-INTESTINAL) 2026 
    Lanreotide for the Prevention of Postoperative Pancreatic Fistula 
     
  • SC30  (SUPPORTIVE CARE) Q4 2025 
    (RATIONAL-PT) Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial 
     
  • SC31 (SUPPORTIVE CARE) Q4 2025
    (TEMPO) Using SMART to optimize the stepped care delivery of a Tailored, dyadic, wEb-based physical activity and self-Management PrOgram for men with prostate cancer and their caregivers 
     
  • SC32S (SUPPORTIVE CARE) Q1 2026
    Feasibility and Acceptability of Collecting Sociodemographic Data in CCTG Trials
     
  • SR8 (SARCOMA) Q1 2027
    (NAPStAR) NeoAdjuvant-only or Peri-operative cemiplimab in high-grade localised soft-tissue SARcoma 
     
  • MA42 (BREAST) Q4 2025 
    (NoLEEta) No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib 
     
  • MAC31 (BREAST) Q1 2026
    (LoTam) Low-Dose Tamoxifen for Patients with Molecular Low-risk Early-Stage Breast Cancer 
     
  • EN12 (GYNECOLOGY)  Q3 2026
    (RAINBO-ORANGE) Treatment of Endometrial Cancer Based on Molecular Features 
     
  • IND246 (SELECTED SOLID TUMORS) Q4 2025 
    (GCAR1) A chimeric antigen receptor (CAR) t-cell therapy in selected relapsed/refractory GPNMB-expressing alveolar soft-part sarcoma, renal cell carcinoma, and triple negative breast cancer 
     
  • IND245 (MANTLE CELL LYMPHOMA) Q4 2025
    Sonrotoclax and Zanubrutinib in patients with relapsed/refractory mantle cell lymphoma receiving standard of care CAR-t cell therapy 
     

Recently activated trials

  • CO33 (BATTMAN) Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma More information >> 
     
  • BR38 (CURB2) Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer More information >> 
     
  • HE2 (SLIDE-HCC) A Phase II Study of STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma  More information >> 
     
  • PR26 (TRIPLE-SWITCH) Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response More information >> 
     
  • SKC1 Neoadjuvant Immunotherapy with Response-Adapted Treatment vs Standard-Of-Care Treatment For Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma More information >>